A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation

Molecular Therapy

Volumn 23, Issue 1, 2015, Pages 24-31

  Small, Donna M ^a   Zani, Marie Louise ^b   Quinn, Derek J ^a   Dallet Choisy, Sandrine ^b   Glasgow, Arlene M A ^a   O'Kane, Cecilia ^a   McAuley, Danny F ^a   McNally, Paul ^c,d   Weldon, Sinéad ^a   Moreau, Thierry ^b   Taggart, Clifford C ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITÉ DE TOURS   (France)

^c OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^d National Children's Research Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ELAFIN; FIBRONECTIN; LIPOPOLYSACCHARIDE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEINASE INHIBITOR; ANTIINFLAMMATORY AGENT; ISOPROTEIN; RECOMBINANT PROTEIN; TIPRELESTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CROSS LINKING; CYSTIC FIBROSIS; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LUNG LAVAGE; MOUSE; NONHUMAN; PNEUMONIA; SERODIAGNOSIS; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN; KINETICS; LUNG; MALE; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PROTEIN DEGRADATION; PROTEIN ENGINEERING;

MUS;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CYSTIC FIBROSIS; ELAFIN; FIBRONECTINS; GENE EXPRESSION; HUMANS; KINETICS; LIPOPOLYSACCHARIDES; LUNG; MALE; MICE; MOLECULAR SEQUENCE DATA; PNEUMONIA; PROTEASE INHIBITORS; PROTEIN ENGINEERING; PROTEIN ISOFORMS; PROTEOLYSIS; RECOMBINANT PROTEINS; TRANSGLUTAMINASES;

EID: 84920682300     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.162     Document Type: Article

References (46)

1. Guyot, N, Zani, ML, Berger, P, Dallet-Choisy, S and Moreau, T (2005). Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafn): evidence for tryptase-mediated generation of elafn. Biol Chem 386: 391-399.
2. Schalkwijk, J, Wiedow, O and Hirose, S (1999). The trappin gene family: proteins defned by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem J 340 (Pt 3): 569-577.
3. Kramps, JA and Klasen, EC (1985). Characterization of a low molecular weight anti-elastase isolated from human bronchial secretion. Exp Lung Res 9: 151-165.
4. Schalkwijk, J, Chang, A, Janssen, P, De Jongh, GJ and Mier, PD (1990). Skin-derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis. Br J Dermatol 122: 631-641.
5. Wiedow, O, Schröder, JM, Gregory, H, Young, JA and Christophers, E (1990). Elafn: an elastase-specifc inhibitor of human skin. Purifcation, characterization, and complete amino acid sequence. J Biol Chem 265: 14791-14795.
6. Mihaila, A and Tremblay, GM (2001). Human alveolar macrophages express elafn and secretory leukocyte protease inhibitor. Z Naturforsch C 56: 291-297.
7. Simpson, AJ, Maxwell, AI, Govan, JR, Haslett, C and Sallenave, JM (1999). Elafn (elastase-specifc inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens. FEBS Lett 452: 309-313.
8. Zani, ML, Baranger, K, Guyot, N, Dallet-Choisy, S and Moreau, T (2009). Protease inhibitors derived from elafn and SLPI and engineered to have enhanced specifcity towards neutrophil serine proteases. Protein Sci 18: 579-594.
9. Butler, MW, Robertson, I, Greene, CM, O'Neill, SJ, Taggart, CC and McElvaney, NG (2006). Elafn prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. J Biol Chem 281: 34730-34735.
10. Baranger, K, Zani, ML, Chandenier, J, Dallet-Choisy, S and Moreau, T (2008). The antibacterial and antifungal properties of trappin-2 (pre-elafn) do not depend on its protease inhibitory function. FEBS J 275: 2008-2020.
11. Williams, SE, Brown, TI, Roghanian, A and Sallenave, JM (2006). SLPI and elafn: one glove, many fngers. Clin Sci (Lond) 110: 21-35.
12. Scott, A, Weldon, S and Taggart, CC (2011). SLPI and elafn: multifunctional antiproteases of the WFDC family. Biochem Soc Trans 39: 1437-1440.
13. Pfundt, R, Wingens, M, Bergers, M, Zweers, M, Frenken, M and Schalkwijk, J (2000). TNF-alpha and serum induce SKALP/elafn gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway. Arch Dermatol Res 292: 180-187.
14. Sallenave, JM, Shulmann, J, Crossley, J, Jordana, M and Gauldie, J (1994). Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specifc inhibitor (ESI/elafn) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol 11: 733-741.
15. Bingle, L, Tetley, TD and Bingle, CD (2001). Cytokine-mediated induction of the human elafn gene in pulmonary epithelial cells is regulated by nuclear factor-kappaB. Am J Respir Cell Mol Biol 25: 84-91.
16. Pfundt, R, van Ruissen, F, van Vlijmen-Willems, IM, Alkemade, HA, Zeeuwen, PL, Jap, PH et al. (1996). Constitutive and inducible expression of SKALP/elafn provides anti-elastase defense in human epithelia. J Clin Invest 98: 1389-1399.
17. Schalkwijk, J, de Roo, C and de Jongh, GJ (1991). Skin-derived antileukoproteinase (SKALP), an elastase inhibitor from human keratinocytes. Purifcation and biochemical properties. Biochim Biophys Acta 1096: 148-154.
18. Wiedow, O, Lüademann, J and Utecht, B (1991). Elafn is a potent inhibitor of proteinase 3. Biochem Biophys Res Commun 174: 6-10.
19. Guyot, N, Zani, ML, Maurel, MC, Dallet-Choisy, S and Moreau, T (2005). Elafn and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. Biochemistry 44: 15610-15618.
20. Nara, K, Ito, S, Ito, T, Suzuki, Y, Ghoneim, MA, Tachibana, S et al. (1994). Elastase inhibitor elafn is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed "cementoin". J Biochem 115: 441-448.
21. Molhuizen, HO, Alkemade, HA, Zeeuwen, PL, de Jongh, GJ, Wieringa, B and Schalkwijk, J (1993). SKALP/elafn: an elastase inhibitor from cultured human keratinocytes. Purifcation, cDNA sequence, and evidence for transglutaminase cross-linking. J Biol Chem 268: 12028-12032.
22. Baranger, K, Zani, ML, Labas, V, Dallet-Choisy, S and Moreau, T (2011). Secretory leukocyte protease inhibitor (SLPI) is, like its homologue trappin-2 (pre-elafn), a transglutaminase substrate. PLoS One 6: e20976.
23. McMichael, JW, Roghanian, A, Jiang, L, Ramage, R and Sallenave, JM (2005). The antimicrobial antiproteinase elafn binds to lipopolysaccharide and modulates macrophage responses. Am J Respir Cell Mol Biol 32: 443-452.
24. Guyot, N, Butler, MW, McNally, P, Weldon, S, Greene, CM, Levine, RL et al. (2008). Elafn, an elastase-specifc inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fbrosis. J Biol Chem 283: 32377-32385.
25. Guyot, N, Bergsson, G, Butler, MW, Greene, CM, Weldon, S, Kessler, E et al. (2010). Functional study of elafn cleaved by Pseudomonas aeruginosa metalloproteinases. Biol Chem 391: 705-716.
26. Kerrin, A, Weldon, S, Chung, AH, Craig, T, Simpson, AJ, O'Kane, CM et al. (2013). Proteolytic cleavage of elafn by 20S proteasome may contribute to infammation in acute lung injury. Thorax 68: 315-321.
27. Kantyka, T, Latendorf, T, Wiedow, O, Bartels, J, Gläser, R, Dubin, G et al. (2009). Elafn is specifcally inactivated by RgpB from Porphyromonas gingivalis by distinct proteolytic cleavage. Biol Chem 390: 1313-1320.
28. Brown, A, Farmer, K, MacDonald, L, Kalsheker, N, Pritchard, D, Haslett, C et al. (2003). House dust mite Der p 1 downregulates defenses of the lung by inactivating elastase inhibitors. Am J Respir Cell Mol Biol 29(3 Pt 1): 381-389.
29. Weldon, S, McNally, P, McElvaney, NG, Elborn, JS, McAuley, DF, Wartelle, J et al. (2009). Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fbrosis lung are due to neutrophil elastase degradation. J Immunol 183: 8148-8156.
30. Wang, Z, Chen, F, Zhai, R, Zhang, L, Su, L, Lin, X et al. (2009). Plasma neutrophil elastase and elafn imbalance is associated with acute respiratory distress syndrome (ARDS) development. PLoS One 4: e4380.
31. Mallia, P, Footitt, J, Sotero, R, Jepson, A, Contoli, M, Trujillo-Torralbo, MB et al. (2012). Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186: 1117-1124.
32. Shaw, L and Wiedow, O (2011). Therapeutic potential of human elafn. Biochem Soc Trans 39: 1450-1454.
33. Maus, U, von Grote, K, Kuziel, WA, Mack, M, Miller, EJ, Cihak, J et al. (2002). The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice. Am J Respir Crit Care Med 166: 268-273.
34. Maus, U, Huwe, J, Maus, R, Seeger, W and Lohmeyer, J (2001). Alveolar JE/MCP-1 and endotoxin synergize to provoke lung cytokine upregulation, sequential neutrophil and monocyte infux, and vascular leakage in mice. Am J Respir Crit Care Med 164: 406-411.
35. Gehrig, S, Duerr, J, Weitnauer, M, Wagner, CJ, Graeber, SY, Schatterny, J et al. (2014). Lack of neutrophil elastase reduces infammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fbrosis-like lung disease. Am J Respir Crit Care Med 189: 1082-1092.
36. Wen, W, Moses, MA, Wiederschain, D, Arbiser, JL and Folkman, J (1999). The generation of endostatin is mediated by elastase. Cancer Res 59: 6052-6056.
37. Perkins, GD, Nathani, N, Richter, AG, Park, D, Shyamsundar, M, Heljasvaara, R et al. (2009). Type XVIII collagen degradation products in acute lung injury. Crit Care 13: R52.
38. Balamayooran, G, Batra, S, Balamayooran, T, Cai, S and Jeyaseelan, S (2011). Monocyte chemoattractant protein 1 regulates pulmonary host defense via neutrophil recruitment during Escherichia coli infection. Infect Immun 79: 2567-2577.
39. Ramnath, RD, Ng, SW, Guglielmotti, A and Bhatia, M (2008). Role of MCP-1 in endotoxemia and sepsis. Int Immunopharmacol 8: 810-818.
40. Mercer, P F, Williams, AE, Scotton, CJ, José, RJ, Sulikowski, M, Moffatt, JD et al. (2014). Proteinase-activated receptor-1, CCL2, and CCL7 regulate acute neutrophilic lung infammation. Am J Respir Cell Mol Biol 50: 144-157.
41. Balamayooran, G, Batra, S, Theivanthiran, B, Cai, S, Pacher, P and Jeyaseelan, S (2012). Intrapulmonary G-CSF rescues neutrophil recruitment to the lung and neutrophil release to blood in Gram-negative bacterial infection in MCP-1-/-mice. J Immunol 189: 5849-5859.
42. Yamaguchi, Y, Matsumura, F, Liang, J, Okabe, K, Ohshiro, H, Ishihara, K et al. (1999). Neutrophil elastase and oxygen radicals enhance monocyte chemoattractant protein-expression after ischemia/reperfusion in rat liver. Transplantation 68: 1459-1468.
43. Bissonnette, EY, Tremblay, GM, Turmel, V, Pirotte, B and Reboud-Ravaux, M (2009). Coumarinic derivatives show anti-infammatory effects on alveolar macrophages, but their anti-elastase activity is essential to reduce lung infammation in vivo. Int Immunopharmacol 9: 49-54.
44. Zani, ML, Nobar, SM, Lacour, SA, Lemoine, S, Boudier, C, Bieth, JG et al. (2004). Kinetics of the inhibition of neutrophil proteinases by recombinant elafn and pre-elafn (trappin-2) expressed in Pichia pastoris. Eur J Biochem 271: 2370-2378.
45. Schägger, H and von Jagow, G (1987). Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100?kDa. Anal Biochem 166: 368-379.
46. Scott, A, Weldon, S, Buchanan, PJ, Schock, B, Ernst, RK, McAuley, DF et al. (2011). Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo. PLoS One 6: e26525.